{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:47:23Z","timestamp":1772120843978,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejso.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T01:57:44Z","timestamp":1618451864000},"page":"2150-2157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence\u2014 results of a prospective multi-centre study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-2873","authenticated-orcid":false,"given":"Snita","family":"Sinukumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-4517","authenticated-orcid":false,"given":"Loma","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-7861","authenticated-orcid":false,"given":"Sanket","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-8964","authenticated-orcid":false,"given":"Sakina","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5099-5443","authenticated-orcid":false,"given":"Nutan","family":"Jumle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-4588","authenticated-orcid":false,"given":"Praveen","family":"Kammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2021.04.003_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.04.015","article-title":"Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer","author":"Liu","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ejso.2021.04.003_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2021.04.003_bib3","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2021.04.003_bib4","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ejso.2021.04.003_bib5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.ejso.2021.04.003_bib6","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.2008.17.0266","article-title":"\u2018Stemness\u2019 genomics law governs clinical behavior of human cancer: implications for decision making in disease management","volume":"26","author":"Glinsky","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2021.04.003_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of CancerN","volume":"332","author":"Van der Burg","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2021.04.003_bib8","first-page":"A646","article-title":"EP1281 Total parietal peritonectomy: what morbidity? and which sites of recurrence?","volume":"29","author":"Hudry","year":"2019","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.ejso.2021.04.003_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2012.11.007","article-title":"Is perioperative visual estimation of intra- abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?","volume":"128","author":"Hynninen","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2021.04.003_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000313823","article-title":"Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer","volume":"33","author":"Lim","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.ejso.2021.04.003_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejogrb.2020.05.058","article-title":"Total extraperitoneal access for parietal peritonectomy for peritoneal surface malignancy: the 'cocoon' technique","volume":"251","author":"Kyriazanos","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejso.2021.04.003_bib12","article-title":"A\u00a0comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - a study by INDEPSO","author":"Sinukumar","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2021.04.003_bib13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1245\/s10434-020-08918-4","article-title":"Total parietal peritonectomy can Be performed with acceptable morbidity for patients with advanced ovarian cancer after neoadjuvant chemotherapy: results from a prospective multi-centric study","volume":"28","author":"Bhatt","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejso.2021.04.003_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Canc Treat Res"},{"key":"10.1016\/j.ejso.2021.04.003_bib16","series-title":"Common Toxicity criteria for adverse events (CTCAE)","year":"2010"},{"issue":"12","key":"10.1016\/j.ejso.2021.04.003_bib17","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ejso.2019.07.019","article-title":"Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential- a prospective multi-centric study","volume":"45","author":"Bhatt","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2021.04.003_bib18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","article-title":"International collaboration on cancer reporting. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"28","author":"McCluggage","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejso.2021.04.003_bib19","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-020-08234-x","article-title":"The pathologic peritoneal cancer index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors","author":"Bhatt","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2021.04.003_bib20","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and val- idation of a system to quantify histopathologic response to neoad- juvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.ejso.2021.04.003_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/IGC.0000000000000843","volume":"27","author":"Gadducci","year":"2017","journal-title":"Int J Gynecol Canc"},{"issue":"36","key":"10.1016\/j.ejso.2021.04.003_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004797","article-title":"Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer","volume":"95","author":"Luo","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejso.2021.04.003_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1245\/s10434-015-4623-z","article-title":"Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer","volume":"22","author":"da Costa","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib25","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","article-title":"Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"20","author":"Petrillo","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib26","first-page":"85","article-title":"Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study","volume":"12","author":"Gao","year":"2019","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.ejso.2021.04.003_bib27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"European organization for research and treatment of cancer-gynaecological cancer group NCIC clinical trials group neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2021.04.003_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2021.04.003_bib29","series-title":"ASO author reflections: total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer\u2014proof-of-principle and analysis of morbidity","author":"Bhatt","year":"2020"},{"issue":"9","key":"10.1016\/j.ejso.2021.04.003_bib30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A\u00a0randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2021.04.003_bib31","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejso.2019.01.009","volume":"45","author":"Bhatt","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib32","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2021.04.003_bib33","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ejso.2021.04.003_bib34","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (peritonectomy procedures) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases","volume":"24","author":"Di Giorgio","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.003_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2013.11.035","article-title":"Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study","volume":"132","author":"Fago-Olsen","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2021.04.003_bib37","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3802\/jgo.2019.30.e25","article-title":"Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer","volume":"30","author":"Tozzi","year":"2019","journal-title":"J\u00a0Gynecol Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832100408X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832100408X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:38:32Z","timestamp":1760060312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832100408X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S074879832100408X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.003","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.28.20141903","asserted-by":"object"}]},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence\u2014 results of a prospective multi-centre study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}